Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Invested Capital (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Invested Capital for 6 consecutive years, with $234.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 15.57% year-over-year to $234.0 million, compared with a TTM value of $234.0 million through Dec 2025, up 15.57%, and an annual FY2025 reading of $234.0 million, up 15.57% over the prior year.
  • Invested Capital was $234.0 million for Q4 2025 at Xeris Biopharma Holdings, up from $218.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $234.1 million in Q1 2022 and bottomed at $19.9 million in Q2 2021.
  • Average Invested Capital over 5 years is $183.6 million, with a median of $200.6 million recorded in 2023.
  • The sharpest move saw Invested Capital soared 966.02% in 2022, then fell 20.71% in 2023.
  • Year by year, Invested Capital stood at $183.3 million in 2021, then increased by 26.71% to $232.3 million in 2022, then dropped by 20.71% to $184.2 million in 2023, then grew by 9.96% to $202.5 million in 2024, then rose by 15.57% to $234.0 million in 2025.
  • Business Quant data shows Invested Capital for XERS at $234.0 million in Q4 2025, $218.6 million in Q3 2025, and $199.3 million in Q2 2025.